Posted by Michael Wonder on 13 Dec 2023
MAPS PBC announces submission of new drug application to the FDA for MDMA assisted therapy for PTSD
12 December 2023 - Filing marks first NDA submission for any psychedelic-assisted therapy.
MAPS Public Benefit Corporation announced the submission of a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified health care provider.
